Svmuu News SpaceX has raised its IPO target valuation to over $2 trillion, as the company prepares to pitch what could be the largest IPO in history to potential investors.
SpaceX's valuation is set to increase by nearly two-thirds within months. In February of this year, following SpaceX's acquisition of Elon Musk's xAI, the combined entity was valued at $1.25 trillion. If it goes public with a valuation exceeding $2 trillion, SpaceX's market capitalization would surpass that of all companies in the S&P 500 except for Nvidia, Apple, Alphabet, Microsoft, and Amazon, and would also exceed Meta and Tesla.
SpaceX has confidentially filed for an IPO, with a listing potentially happening as early as June. The company is expected to raise up to $75 billion, far exceeding the previous record for the largest IPO—Saudi Aramco's $29 billion offering in 2019. The raised funds will be used for projects including space-based AI data centers and lunar factories.
SpaceX has selected Bank of America, Citigroup, Goldman Sachs, JPMorgan Chase, and Morgan Stanley as the lead underwriters for the IPO. The company plans to hold a bank syndicate conference call next Monday, with analyst briefings scheduled for later in April. Bloomberg Intelligence analysts noted that SpaceX's revenue for 2026 is approaching $20 billion, with its launch business and Starlink contributing the majority of the income.
SpaceX IPO Target Valuation Exceeds $2 Trillion, Plans to Raise Up to $75 Billion
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
5
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
6
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
9
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
-
10
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
Markets Today
Recommended Reading








